Evidence map›Paper›PMID 31171735›Full record

ArticleThe oncologist2019

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors.

M Dror Michaelson, Shilpa Gupta, Neeraj Agarwal, Russell Szmulewitz, Thomas Powles, Roberto Pili, Justine Yang Bruce, Ulka Vaishampayan, James Larkin, Brad Rosbrook and 6 more

Open access · bronzeAbstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. The MET Oncogene Network of Interacting Cell Surface Proteins.International journal of molecular sciences · 2024
    Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 13 institutions in 4 countries.

M Dror MichaelsonClaire and John Bertucci Center for Genitourinary Cancers, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA dmichaelson1@mgh.harvard.edu.
Shilpa GuptaMasonic Cancer Center, Minneapolis, Minnesota, USA.
Neeraj AgarwalHuntsman Cancer Institute, Salt Lake City, Utah, USA.
Russell SzmulewitzUniversity of Chicago, Chicago, Illinois, USA.
Thomas PowlesBarts Cancer Institute, London, UK.
Roberto PiliIndiana University, Indianapolis, Indiana, USA.
Justine Yang BruceUniversity of Wisconsin, Madison, Wisconsin, USA.
Ulka VaishampayanKarmanos Cancer Center, Detroit, Michigan, USA.
James LarkinThe Royal Marsden, London, UK.
Brad RosbrookPfizer Oncology, San Diego, California, USA.
Erjian WangPfizer Oncology, San Diego, California, USA.
Danielle MurphyPfizer Oncology, San Diego, California, USA.
Panpan WangPfizer Oncology, Shanghai, People's Republic of China.
Maria Josè LechugaPfizer Oncology, Milan, Italy.
Olga ValotaPfizer Oncology, Milan, Italy.
Dale R ShepardCleveland Clinic, Cleveland, Ohio, USA.
Pfizer (United States) · USPfizer (Italy) · ITBarts Health NHS Trust · GBCleveland Clinic · USHuntsman Cancer Institute · USIndiana University – Purdue University Indianapolis · USMasonic Cancer CenterMassachusetts General Hospital · USPfizer (China) · CNRoyal Marsden Hospital · GBThe Barbara Ann Karmanos Cancer Institute · USUniversity of Chicago · USUniversity of Wisconsin–Madison · US

Funding

Project 4: Role of Receptor Tyrosine Kinase AXL in HNSCC Therapy ResistanceP50DE026787 · NIDCR · UNIVERSITY OF WISCONSIN-MADISON · PI YU, MENGGANG · 2016 to 2020
$10.8M
NIDCR NIH HHS P50 DE026787
6 · The paper itself

Abstract

lessons learnedThe combination of axitinib and crizotinib has a manageable safety and tolerability profile, consistent with the profiles of the individual agents when administered as monotherapy.The antitumor activity reported here for the combination axitinib/crizotinib does not support further study of this combination treatment in metastatic renal cell carcinoma given the current treatment landscape.

backgroundVascular endothelial growth factor (VEGF) inhibitors have been successfully used to treat metastatic renal cell carcinoma (mRCC); however, resistance eventually develops in most cases. Tyrosine protein kinase Met (MET) expression increases following VEGF inhibition, and inhibition of both has shown additive effects in controlling tumor growth and metastasis. We therefore conducted a study of axitinib plus crizotinib in advanced solid tumors and mRCC.

methodsThis phase Ib study included a dose-escalation phase (starting doses: axitinib 3 mg plus crizotinib 200 mg) to estimate maximum tolerated dose (MTD) in patients with solid tumors and a dose-expansion phase to examine preliminary efficacy in treatment-naïve patients with mRCC. Safety, pharmacokinetics, and biomarkers were also assessed.

resultsNo patients in the dose-escalation phase (

conclusionThe combination of axitinib plus crizotinib, at estimated MTD, had a manageable safety profile and showed evidence of modest antitumor activity in mRCC.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsAxitinibCarcinoma, Renal CellCrizotinibDose-Response Relationship, DrugFemaleHumansKidney NeoplasmsMaleMiddle AgedPatient SafetyTissue DistributionAxitinibCrizotinib

Identifiers

PMID31171735
PMCPMC6738313
OpenAlexW2948155582

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.